Podcast Episodes

378: Merck's heart disease win and the FDA's new drug regulator

What does Rick Pazdur's new role mean for the Food and Drug Administration? Has Merck solved the PCSK9 access issue? And how much credit can the pres…

11 months, 1 week ago

377: Melodrama at the FDA and the Pfizer-Novo bidding war

On a jam-packed show, your co-hosts, minus the vacationing Allison DeAngelis, chat with STAT’s D.C. correspondent Lizzy Lawrence about a slow-boiling…

11 months, 2 weeks ago

376: BridgeBio’s great week and Moderna’s unraveling

Has BridgeBio’s business model worked? How are executives at Moderna dealing with the company’s slump? And who will the hosts dress up as for Hallowe…

11 months, 3 weeks ago

375: Startups push the FDA and biotech booms in North Carolina

Can Trump take credit for North Carolina's booming biopharma industry? Which drugs could get a shortcut to the market? And who wore a tuxedo to the S…

11 months, 4 weeks ago

374: Veteran biotech executive Clive Meanwell on drug pricing and the obesity market

On this week’s episode of “The Readout LOUD”: an interview with veteran biotech executive and company founder Clive Meanwell. Pfizer recently acquire…

1 year ago

373: Party in biotech land and AstraZeneca’s miscalculation

Where did former vaccine regulator Peter Marks find a new job? How did a math error cost AstraZeneca a rare disease candidate? And is biotech back?

W…

1 year ago

372: A pharma C-suite shakeup and Trump's deal with Pfizer

How will we look back on Emma Walmsley's tenure as GSK's CEO? Why did one of the FDA's top drug officials call out an obscure lupus drug on LinkedIn?…

1 year ago

371: A gene therapy success in Huntington's and Trump's autism announcement

We bring on UniQure CEO Matt Kapusta to discuss the company's announcement this week that its one-time treatment for Huntington’s disease significant…

1 year ago

370: Pharma sours on the U.K., plus biotech M&A's quiet roll

STAT's European correspondent Andrew Joseph calls in from the U.K. to the podcast to dissect why companies like Merck and GSK are putting their money…

1 year, 1 month ago

369: Trump, Chinese biotech, and an industry career reshaped by illness

Listeners of this podcast probably know pharma consultant Mike Rea for his annual ranking of drug company R&D productivity. But this week, he penned …

1 year, 1 month ago